Last updated on January 2016

E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma


Brief description of study

E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Detailed Study Description

The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on Diffuse Large B Cell Lymphoma.

Clinical Study Identifier: TX3060

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Drashti Shah

AMITA Health
Arlington Heights, IL USA
  Connect »